WO2000025827A3 - Dna molecules encoding muc-1 and use thereof in tumor vaccination - Google Patents

Dna molecules encoding muc-1 and use thereof in tumor vaccination Download PDF

Info

Publication number
WO2000025827A3
WO2000025827A3 PCT/EP1999/007874 EP9907874W WO0025827A3 WO 2000025827 A3 WO2000025827 A3 WO 2000025827A3 EP 9907874 W EP9907874 W EP 9907874W WO 0025827 A3 WO0025827 A3 WO 0025827A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna molecules
molecules encoding
tumor vaccination
encoding muc
tumor
Prior art date
Application number
PCT/EP1999/007874
Other languages
French (fr)
Other versions
WO2000025827A2 (en
Inventor
Dino Parente
MASSIMO Anna Maria DI
Santis Rita De
Original Assignee
Menarini Ricerche Spa
Dino Parente
Massimo Anna Maria Di
Santis Rita De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SK571-2001A priority Critical patent/SK5712001A3/en
Application filed by Menarini Ricerche Spa, Dino Parente, Massimo Anna Maria Di, Santis Rita De filed Critical Menarini Ricerche Spa
Priority to CA002348745A priority patent/CA2348745A1/en
Priority to EA200100395A priority patent/EA200100395A1/en
Priority to BR9914892-7A priority patent/BR9914892A/en
Priority to HU0103784A priority patent/HUP0103784A2/en
Priority to PL99348156A priority patent/PL348156A1/en
Priority to MXPA01004186A priority patent/MXPA01004186A/en
Priority to JP2000579265A priority patent/JP2002528519A/en
Priority to AU11522/00A priority patent/AU1152200A/en
Priority to EP99971329A priority patent/EP1124956A2/en
Publication of WO2000025827A2 publication Critical patent/WO2000025827A2/en
Publication of WO2000025827A3 publication Critical patent/WO2000025827A3/en
Priority to BG105458A priority patent/BG105458A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided herein is a pharmaceutical composition containing one or more DNA molecules encoding fragments of a protein overexpressed in tumor cells, in order to induce an anti-tumor Ag-specific immune response, in association with suitable excipients and adjuvants.
PCT/EP1999/007874 1998-10-30 1999-10-18 Dna molecules encoding muc-1 and use thereof in tumor vaccination WO2000025827A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PL99348156A PL348156A1 (en) 1998-10-30 1999-10-18 Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect
CA002348745A CA2348745A1 (en) 1998-10-30 1999-10-18 Dna molecules encoding muc-1 and use thereof in tumor vaccination
EA200100395A EA200100395A1 (en) 1998-10-30 1999-10-18 PHARMACEUTICAL COMPOSITION CONTAINING DNA FRAGMENTS ENCODING ANTIGENIC PROTEIN COATING ANTI-ANTITROTHAL EFFECT
BR9914892-7A BR9914892A (en) 1998-10-30 1999-10-18 Pharmaceutical composition, containing fragments of a DNA encoding antigenic protein with antitumor effect
HU0103784A HUP0103784A2 (en) 1998-10-30 1999-10-18 Dna molecules encoding muc-1 and use thereof in tumor vaccination
SK571-2001A SK5712001A3 (en) 1998-10-30 1999-10-18 Pharmaceutical composition
MXPA01004186A MXPA01004186A (en) 1998-10-30 1999-10-18 Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect.
EP99971329A EP1124956A2 (en) 1998-10-30 1999-10-18 Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect
AU11522/00A AU1152200A (en) 1998-10-30 1999-10-18 Pharmaceutical composition, containing fragments of an antigenic protein encoding dna endowed with anti-tumor effect
JP2000579265A JP2002528519A (en) 1998-10-30 1999-10-18 Pharmaceutical composition containing DNA encoding an antigenic protein having antitumor effect
BG105458A BG105458A (en) 1998-10-30 2001-04-20 Dna molecules encoding muc-1 and use thereof in tumor vaccination

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998MI002330A IT1303683B1 (en) 1998-10-30 1998-10-30 PHARMACEUTICAL COMPOSITION WITH ANTI-TUMORAL ACTION CONTAINING DNACODIFIER FOR FRAGMENTS OF AN ANTIGENIC PROTEIN.
ITMI98A002330 1998-10-30

Publications (2)

Publication Number Publication Date
WO2000025827A2 WO2000025827A2 (en) 2000-05-11
WO2000025827A3 true WO2000025827A3 (en) 2000-08-10

Family

ID=11380969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/007874 WO2000025827A2 (en) 1998-10-30 1999-10-18 Dna molecules encoding muc-1 and use thereof in tumor vaccination

Country Status (19)

Country Link
EP (1) EP1124956A2 (en)
JP (1) JP2002528519A (en)
CN (1) CN1324406A (en)
AR (1) AR020927A1 (en)
AU (1) AU1152200A (en)
BG (1) BG105458A (en)
BR (1) BR9914892A (en)
CA (1) CA2348745A1 (en)
CO (1) CO5231134A1 (en)
CZ (1) CZ20011521A3 (en)
EA (1) EA200100395A1 (en)
HU (1) HUP0103784A2 (en)
IT (1) IT1303683B1 (en)
MX (1) MXPA01004186A (en)
PE (1) PE20001287A1 (en)
PL (1) PL348156A1 (en)
SK (1) SK5712001A3 (en)
TR (1) TR200101141T2 (en)
WO (1) WO2000025827A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
JP2003533181A (en) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート Mucin-1 derived antigen and its use in immunotherapy
EP1317278B1 (en) * 2000-09-11 2009-11-11 Dana-Farber Cancer Institute, Inc. Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
JP4276432B2 (en) 2000-12-22 2009-06-10 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド Method for regulating cell growth by MUC1
CA2519953C (en) * 2003-03-24 2016-01-05 The Scripps Research Institute Dna vaccine against tumor growth and methods of use thereof
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US7871784B2 (en) 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
CN106279435B (en) * 2016-08-16 2019-06-07 新乡医学院 Target anti-tumor vaccine, encoding gene, expression vector, expression engineering bacteria and the application of VEGF and mucin1
CN114230655A (en) * 2021-03-24 2022-03-25 深圳市新靶向生物科技有限公司 Antigenic peptide combination related to esophageal cancer driver gene mutation and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011982A1 (en) * 1993-10-25 1995-05-04 Menarini Ricerche Sud S.P.A. Expression system for eukaryotic cell lines
WO1998037095A2 (en) * 1997-02-24 1998-08-27 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011982A1 (en) * 1993-10-25 1995-05-04 Menarini Ricerche Sud S.P.A. Expression system for eukaryotic cell lines
WO1998037095A2 (en) * 1997-02-24 1998-08-27 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANTON ET AL: "MHC CLASS I-ASSOCIATED PEPTIDES PRODUCED FROM ENDOGENOUS GENE PRODUCTS WITH VASTLY DIFFERENT EFFICICIENCES", THE JOURNAL OF IMMUNOLOGY, vol. 158, 1997, pages 2535 - 2542, XP002136996 *
CHAU V ET AL: "A MULTIUBIQUITIN CHAIN IS CONFINED TO SPECIFIC LYSINE IN A TARGETED SHORT-LIVED PROTEIN", SCIENCE (WASHINGTON D C) 1989, vol. 243, no. 4898, 1989, pages 1576 - 1589, XP002136993, ISSN: 0036-8075 *
GENDLER S J ET AL: "MOLECULAR CLONING AND EXPRESSION OF HUMAN TUMOR-ASSOCIATED POLYMORPHIC EPITHELIAL MUCIN", JOURNAL OF BIOLOGICAL CHEMISTRY 1990, vol. 265, no. 25, 1990, pages 15286 - 15293, XP002136995, ISSN: 0021-9258 *
GRAHAM R A ET AL: "The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine", CANCER IMMUNOLOGY AND IMMUNOTHERAPY,DE,BERLIN, vol. 2, no. 42, 1 January 1996 (1996-01-01), pages 71 - 80, XP002075466, ISSN: 0340-7004 *
GRANT ETHAN P ET AL: "Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation.", JOURNAL OF IMMUNOLOGY 1995, vol. 155, no. 8, 1995, pages 3750 - 3758, XP002136994, ISSN: 0022-1767 *
RODRIGUEZ FERNANDO ET AL: "DNA immunization: Ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction.", JOURNAL OF VIROLOGY 1997, vol. 71, no. 11, 1997, pages 8497 - 8503, XP002136992, ISSN: 0022-538X *
TAYLOR-PAPADIMITRIOU J AND EPENETOS A A: "Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy", TIBTECH,GB,CAMBRIDGE, no. 12, 1 January 1994 (1994-01-01), pages 227 - 233, XP002075467 *

Also Published As

Publication number Publication date
IT1303683B1 (en) 2001-02-23
CZ20011521A3 (en) 2001-10-17
CO5231134A1 (en) 2002-12-27
PE20001287A1 (en) 2000-12-07
SK5712001A3 (en) 2002-04-04
ITMI982330A0 (en) 1998-10-30
TR200101141T2 (en) 2001-09-21
JP2002528519A (en) 2002-09-03
HUP0103784A2 (en) 2002-02-28
BR9914892A (en) 2001-07-17
EP1124956A2 (en) 2001-08-22
CN1324406A (en) 2001-11-28
AU1152200A (en) 2000-05-22
BG105458A (en) 2002-06-28
WO2000025827A2 (en) 2000-05-11
CA2348745A1 (en) 2000-05-11
PL348156A1 (en) 2002-05-06
ITMI982330A1 (en) 2000-04-30
EA200100395A1 (en) 2001-10-22
MXPA01004186A (en) 2002-06-04
AR020927A1 (en) 2002-06-05

Similar Documents

Publication Publication Date Title
AU3472299A (en) Rna cancer vaccine and methods for its use
WO2000012127A3 (en) Dna cancer vaccine and methods for its use
WO2004016734A3 (en) Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer
WO2003022995A3 (en) Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
WO2003040340A3 (en) Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
WO2000025827A3 (en) Dna molecules encoding muc-1 and use thereof in tumor vaccination
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
AU6117696A (en) Nucleic acid respiratory syncytial virus vaccines
WO1998037095A3 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
WO2002016598A3 (en) Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers
NZ292565A (en) Production of stabilised complement protein-3 convertase
AU1725797A (en) Parapoxviruses which contain foreign DNA, their preparation and their use in vaccines
FR2590483B1 (en) PURIFIED ANTIGENS HAVING VACCINATION PROPERTIES AGAINST B. PERTUSSIS, IN PARTICULAR RECOMBINANT DNA MEANS, AND VACCINE COMPOSITIONS CONTAINING THEM
IL122455A0 (en) Hapten modified tumor cell extract and methods of treating or screening for cancer
EP2366711A3 (en) Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
WO2004067716A3 (en) Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
WO2002014361A3 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
WO2002060953A3 (en) Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
PT1573022E (en) Nucleic acid and corresponding protein entitled 184p1e2 useful in treatment and detection of cancer
WO2002092842A3 (en) Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer
WO2002018578A3 (en) Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
AU6897098A (en) Saponin adjuvants in combination with dna vaccination
WO2001055391A3 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
WO2002014501A3 (en) Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer
WO2003020954A3 (en) 205p1b5 in treatment and detection of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99812745.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2000 11522

Country of ref document: AU

Kind code of ref document: A

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 1999 105458

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/004186

Country of ref document: MX

Ref document number: 2001/01141

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2348745

Country of ref document: CA

Ref document number: 2348745

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2000 579265

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09830513

Country of ref document: US

Ref document number: 5712001

Country of ref document: SK

Ref document number: IN/PCT/2001/591/CHE

Country of ref document: IN

Ref document number: 1999971329

Country of ref document: EP

Ref document number: PV2001-1521

Country of ref document: CZ

Ref document number: 200100395

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999971329

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2001-1521

Country of ref document: CZ

CFP Corrected version of a pamphlet front page

Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWR Wipo information: refused in national office

Ref document number: PV2001-1521

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1999971329

Country of ref document: EP